Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir

Gentile, 2014, The first of a new class of drugs targeted against hepatitis C virus NS5A, Curr Med Chem, 21, 1391, 10.2174/0929867321666131228222215 McConachie, 2016, New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir, Expert Rev Clin Pharmacol, 9, 287, 10.1586/17512433.2016.1129272 McCormack, 2016, Daclatasvir in hepatitis C virus infection: a guide to its use in the EU, Drugs Ther Perspect, 32, 42, 10.1007/s40267-015-0272-3 Keating, 2016, Daclatasvir: a review in chronic hepatitis C, Drugs, 76, 1381, 10.1007/s40265-016-0632-x Jiang, 2012, A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine, J Chromatogr A, 1245, 117, 10.1016/j.chroma.2012.05.028 Jiang, 2015, Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma, J Pharm Biomed Anal, 107, 409, 10.1016/j.jpba.2015.01.027 Rezk, 2016, Development and validation of sensitive and rapid UPLC-MS/MS method for quantitative determination of daclatasvir in human plasma: application to a bioequivalence study, J Pharm Biomed Anal, 128, 61, 10.1016/j.jpba.2016.05.016 Srinivasu, 2016, Development and validation of the chiral HPLC method for daclatasvir in gradient elution mode on amylose-based immobilized chiral stationary phase, Chromatographia, 79, 1457, 10.1007/s10337-016-3157-2 Ashok Chakravarthy, 2016, Method development and validation of assay and dissolution methods for the estimation of daclatasvir in tablet dosage forms by reverse phase HPLC, Eur J Pharm Med Res, 3, 356 http://www.drugbank.ca/ (last time accessed: October 1st, 2016). ICH, 2005